Coherus Oncology (CHRS) Total Liabilities (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Total Liabilities data on file, last reported at $187.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 66.21% year-over-year to $187.4 million; the trailing twelve-month figure through Mar 2026 stood at $187.4 million (down 66.21% YoY), and the FY2025 full-year result was $197.3 million, down 66.01% from the prior year.
• Total Liabilities eased to $187.4 million in Q1 2026, from $197.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $845.4 million in Q1 2024 to a low of $187.4 million in Q1 2026.
• A 5-year average of $568.5 million and a median of $593.0 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 41.15% in 2024 and plunged 66.21% in 2026, its largest moves.
• Tracing CHRS's Total Liabilities over 5 years: stood at $618.3 million in 2022, then jumped by 33.12% to $823.0 million in 2023, then declined by 29.47% to $580.5 million in 2024, then plunged by 66.01% to $197.3 million in 2025, then dropped by 5.03% to $187.4 million in 2026.
• Business Quant data shows CHRS's Total Liabilities at $187.4 million in Q1 2026, $197.3 million in Q4 2025, and $428.7 million in Q3 2025.